Clinical Trial Update: Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lenvatinib plus DEB-TACE with HAIC versus lenvatinib plus DEB-TACE in patients with large hepatocellular carcinoma and portal vein tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 3 | Status: RECRUITING